St. Louis Financial Planners Asset Management LLC Buys New Holdings in AbbVie Inc. $ABBV

St. Louis Financial Planners Asset Management LLC purchased a new position in AbbVie Inc. (NYSE:ABBV) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 19,202 shares of the company’s stock, valued at approximately $5,013,000. AbbVie makes up about 2.6% of St. Louis Financial Planners Asset Management LLC’s investment portfolio, making the stock its 7th largest holding.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the fourth quarter worth $28,000. Imprint Wealth LLC increased its holdings in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the last quarter. Legacy Wealth Managment LLC ID lifted its stake in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new stake in AbbVie in the 4th quarter worth $31,000. Finally, WestEnd Advisors LLC boosted its holdings in shares of AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ABBV. Cantor Fitzgerald raised their price objective on AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research report on Monday. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 30th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Finally, Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $275.70.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie delivered a robust second quarter, with earnings and revenue exceeding analyst expectations. Revenue increased approximately 10% year over year, while management raised its revenue outlook and cited continued momentum from key products. ABBV Stock Dips 4% Despite Robust Q2
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group Bank upgraded AbbVie from “hold” to “buy,” and Cantor Fitzgerald raised its price target to $285, suggesting potential upside from current levels. Cantor Fitzgerald Boosts AbbVie Price Target
• Positive Sentiment: AbbVie’s long-running dividend-growth record continues to support its appeal to income-focused investors, providing a potential floor for the stock despite valuation and acquisition concerns. This Stock Keeps Raising Its Dividend
• Neutral Sentiment: The Apogee acquisition is intended to expand AbbVie’s growth pipeline, but investors are assessing whether the strategic benefits will justify the transaction’s cost and integration risks. Baron Capital Exits Apogee Therapeutics
• Negative Sentiment: AbbVie reduced its 2026 adjusted EPS outlook to reflect the Apogee deal, offsetting the positive quarterly results and higher revenue guidance. The lower earnings forecast appears to be the main catalyst behind the stock’s decline. ABBV Stock Dips 4% Despite Robust Q2
• Negative Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund the acquisition. The financing increases debt obligations and may intensify concerns about leverage, interest expense, and near-term shareholder returns. AbbVie Prices Senior Notes to Fund Acquisition

AbbVie Trading Down 1.0%

Shares of NYSE ABBV opened at $243.64 on Friday. The firm’s 50-day moving average price is $241.40 and its 200-day moving average price is $224.82. The stock has a market capitalization of $430.46 billion, a price-to-earnings ratio of 68.82, a P/E/G ratio of 0.82 and a beta of 0.30. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the firm earned $2.97 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts predict that AbbVie Inc. will post 14.06 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s payout ratio is 195.48%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.